LifeLUNG Improving Life expectancy of LUNG transplant recipients through innovative ex vivo perfusion gene therapy
- Coordinator
- Katholieke Universiteit Leuven, Belgium
- Runs
- 1 November 2025 to 31 October 2029
- Status
- Running
- EU funding
- €4.2m
- Total cost
- —
- Partners
- 24 organisations in 11 countries
- Type
- Marie Skłodowska-Curie Action
- Grant agreement
- 101227159
What the project is doing
In the project's own words, from its summary on CORDIS.
Patient survival after lung transplantation (LTx) for end-stage pulmonary disease is poor (5-year survival rate of 59%) due to ischemia reperfusion injury (IRI) and graft rejection. No therapies are available to prevent IRI, and current immunosuppression causes toxicity and morbidity. Novel strategies are required that can mask the graft from the recipient’s immune systemThe LifeLUNG initiative unites the critical building blocks available in Europe to advance towards a novel paradigm for LTx.
Ex vivo lung perfusion (EVLP) is a clinically used platform to maintain active lung physiology outside the body, making pre-LTx organ engineering a reality. The project aims to advancing EVLP technology to enhance our understanding of transplant rejection through accessible models. By utilizing biobanks of lung biopsies from both clinical LTx cases and established animal models of IRI and rejection, LifeLUNG will apply advanced machine learning and AI-driven deep sequencing to identify key immune factors and gene targets.
The latter will be targeted in LifeLUNG with gene therapeutic agents (GTAs) that can be delivered during EVLP to selectively modulate immune responses. Several delivery tools including adeno-associated viral vectors, virus-like particles and lipid nanoparticles, will be tailored to ensure precise and graft-specific gene modulation, enhancing the therapeutic potential for reducing IRI and preventing rejection. Also the efficient production strategies of these GTAs will be an integral part of LifeLUNG.
In parallel, LifeLUNG will explore the economic and ethical paradigms of genetic modification of lung transplantation and reflect its implementation into the broader research and clinical framework. The interdisciplinary nature of LifeLUNG will support the training of 15 doctoral candidates across clinical, academic, and industrial sectors, fostering collaboration and the development of transferable skills to advance the research objectives.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Katholieke Universiteit Leuven | Leuven | Belgium | Coordinator |
| Medizinische Universitaet Wien | Wien | Austria | Participant |
| QbD Group Austria GmbH | Vienna | Austria | Associatedpartner |
| Antleron | Louvain | Belgium | Participant |
| HALO, Patiëntenvereniging longtransplantatie UZ Leuven | Oostrozebeke | Belgium | Associatedpartner |
| Universitat Basel | Basel | Switzerland | Associatedpartner |
| Eberhard Karls Universitaet Tuebingen | Tuebingen | Germany | Participant |
| Miltenyi Biotec BV & Co Kg | Bergisch Gladbach | Germany | Participant |
| Aarhus Universitet | Aarhus C | Denmark | Participant |
| Fundacion Hitt | Barcelona | Spain | Participant |
| Omniscope Espana SL | Barcelona | Spain | Participant |
| Universitat De Barcelona | Barcelona | Spain | Associatedpartner |
| Universitat Internacional De Catalunya | Barcelona | Spain | Associatedpartner |
| Association Hopital Foch | Suresnes Cedex | France | Participant |
| Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement | Paris | France | Associatedpartner |
| Universite Paris-Saclay | Gif-Sur-Yvette | France | Associatedpartner |
| Stichting Eurotransplant International Foundation | Leiden | Netherlands | Associatedpartner |
| Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | Participant |
| Universiteit Utrecht | Utrecht | Netherlands | Associatedpartner |
| Astrazeneca AB | Sodertaelje | Sweden | Associatedpartner |
| Lunds Universitet | Lund | Sweden | Participant |
| Xvivo Perfusion Aktiebolag | Goteborg | Sweden | Associatedpartner |
| University College London | London | United Kingdom | Participant |
| Mary Ann Liebert, Inc. | New Rochelle | United States | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI